Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Obesity Right
  3. Zepbound (tirzepatide) injection Right
  4. Is the formulation of Zepbound® (tirzepatide) the same in the single-dose pen and single-dose vial?
Search Zepbound (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Zepbound ® (tirzepatide) injection

2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Is the formulation of Zepbound® (tirzepatide) the same in the single-dose pen and single-dose vial?

The tirzepatide single-dose pen and single-dose vial contain the identical active ingredient, tirzepatide. They also contain the same inactive ingredients.

US_cFAQ_TZPCWM360_INGREDIENTS_ALL_PRESENTATIONS_CWM
US_cFAQ_TZPCWM360_INGREDIENTS_ALL_PRESENTATIONS_CWMen-US

See important safety information, including boxed warning, in the attached prescribing information.

Formulation of Approved Zepbound Presentations

Zepbound (tirzepatide) is approved by the Food and Drug Administration (FDA) in a 

  • single-dose pen, and
  • single-dose vial.1

The single-dose pen and single-dose vial have the identical active ingredient, tirzepatide, and are designed to deliver the same doses.1

Regardless of presentation, tirzepatide is administered subcutaneously once weekly, and the dosing regimen and administration sites (abdomen, thigh or back of upper arm) remain the same.1

Attributes of the Tirzepatide Single-Dose Vial Versus Single-Dose Pen

The tirzepatide formulation provided in the single-dose vial is the same as in the single-dose pen that was tested in the SURMOUNT clinical trial program in adults with obesity or overweight or moderate-to-severe obstructive sleep apnea and obesity.1-6

This includes the same excipients, excipient concentrations, and drug substance concentration.7

The single-dose vial and single-dose pen contain 1 fixed dose and have a dosing volume of 0.5 mL per dose.1

Both the single-dose vial and single-dose pen are for single use and do not contain preservatives.1

Enclosed Prescribing Information

ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.

2Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038

3Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X

4Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. https://doi.org/10.1038/s41591-023-02597-w

5Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945

6Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. https://doi.org/10.1056/NEJMoa2404881

7Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: January 09, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly